Mode
Text Size
Log in / Sign up
Phase 4 Completed N=80 Randomized Double-blind Treatment

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

chronic rhinosinusitis · Chronic Eosinophilic Rhinosinusitis · Allergic Rhinosinusitis
Source: ClinicalTrials.gov NCT02696850 ↗
Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcomePrimary: Change in SNOT-22 (Sino-Nasal Outcome Test) — 20.7; 13.6 score on a scale
◆ Published Evidence
Established
73citations · ~9 / year
Effect of Budesonide Added to Large-Volume, Low-pressure Saline Sinus Irrigation for Chronic Rhinosinusitis: A Randomized Clinical Trial.
JAMA otolaryngology-- head & neck surgery · 2018 · Open access · Likely link

Summary

The goal of this research project is to explore the impact of the addition of budesonide to high-volume, low-pressure nasal sinus saline irrigation (aka "Neti-Pot"-type systems) for patients with chronic rhinosinusitis with or without nasal polyps.

Linked Publications

  • Effect of Budesonide Added to Large-Volume, Low-pressure Saline Sinus Irrigation for Chronic Rhinosinusitis: A Randomized Clinical Trial.
    JAMA otolaryngology-- head & neck surgery · 2018 · 73 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in SNOT-22 (Sino-Nasal Outcome Test)
20.7; 13.6
SECONDARY
Clinical Global Impression of Change (CGI)
24; 20

Eligibility Criteria

Inclusion Criteria

Twelve (12) weeks or longer of two or more of the following signs and symptom consistent with chronic rhinosinusitis (CRS)

  • mucopurulent drainage (anterior, posterior, or both), nasal obstruction (congestion),facial pain-pressure-fullness, and decreased sense of smell

AND inflammation documented by one or more of the following findings:

  • purulent (not clear) mucus or edema in the middle meatus or ethmoid region,
  • polyps in nasal cavity or the middle meatus, and/or
  • radiographic imaging showing inflammation of the paranasal sinuses

Exclusion Criteria

  • Unable to speak English
  • History of comorbid ciliary dyskinesia, cystic fibrosis or any other mucociliary condition
  • Dependence on prolonged corticosteroid therapy for comorbid conditions, such as asthma and chronic obstructive pulmonary disease.
  • History of oral or systematic antibiotic use in the past 2 weeks
  • History of nasal or sinus surgery within past 6 weeks
  • History of cerebrospinal fluid leak
  • History of allergy to budesonide or other topical steroids
  • Pregnant or breast feeding
  • Current infection or history of one of the following infections: Tuberculosis (TB) lung infection, or Herpes infection of the eye.
  • Baseline SNOT-22 total scores below 9 were excluded due to the inability to achieve a minimally clinically improved difference
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02696850) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search